Efficacy of Onalespib, a Long-Acting Second-Generation HSP90 Inhibitor, as a Single Agent and in Combination with Temozolomide against Malignant Gliomas
Alessandro Canella(Nationwide Children's Hospital), Vinay K. Puduvalli(The University of Texas MD Anderson Cancer Center), Joseph K. Liu(Monash University), Frederick F. Lang(The University of Texas MD Anderson Cancer Center), Alessandra M. Welker(Harvard University), Prabakaran Nagarajan(The Ohio State University), Balveen Kaur(Augusta University), Deepa Sampath(The University of Texas MD Anderson Cancer Center), Erik P. Sulman(NYU Langone Health), Joy Gumin(The University of Texas MD Anderson Cancer Center), Metin N. Gürcan(Wake Forest University), Fazly Salleh Abas(The Ohio State University Wexner Medical Center), Jihong Xu, Christine E. Beattie(The Ohio State University), Divya Kesanakurti(University of Illinois Urbana-Champaign), Ji Young Yoo(The University of Texas MD Anderson Cancer Center)
Cited by 69
Related Papers
A Randomized Trial of Bevacizumab for Newly Diagnosed Glioblastoma
|New England Journal of Medicine|2014|2.8k
Cyclophosphamide enhances glioma virotherapy by inhibiting innate immune responses
|Proceedings of the National Academy of Sciences|2006|360
Glucose-Mediated N-glycosylation of SCAP Is Essential for SREBP-1 Activation and Tumor Growth
|Cancer Cell|2015|336
Inhibition of SOAT1 Suppresses Glioblastoma Growth via Blocking SREBP-1–Mediated Lipogenesis
|Clinical Cancer Research|2016|332